Scarica l'app Stockscreener
2.63
2.94%
0.075
Dopo l'orario di chiusura:
2.71
0.08
+3.04%
Panoramica
Notizia
Cronologia dei prezzi
Financials
Perché AYTU Giù?
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$2.555
Aprire:
$2.59
Volume 24 ore:
43,699
Relative Volume:
0.03
Capitalizzazione di mercato:
$23.61M
Reddito:
$93.76M
Utile/perdita netta:
$-13.68M
Rapporto P/E:
-1.00
EPS:
-2.63
Flusso di cassa netto:
$8.77M
1 W Prestazione:
+13.36%
1M Prestazione:
+32.83%
6M Prestazione:
+57.49%
1 anno Prestazione:
-5.40%
Intervallo 1D:
$2.59
$2.6499
Intervallo di 1 settimana:
$2.2969
$2.6499
Portata 52W:
$0.95
$2.85
Aytu Biopharma Inc Stock (AYTU) Company Profile
Nome
Aytu Biopharma Inc
Settore
Telefono
(720) 437-6580
Indirizzo
7900 E. UNION AVENUE, DENVER
Confronta AYTU con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
AYTU
Aytu Biopharma Inc
|
2.63 | 22.94M | 93.76M | -13.68M | 8.77M | -2.63 |
|
ZTS
Zoetis Inc
|
153.45 | 67.31B | 9.29B | 2.52B | 2.28B | 5.57 |
|
TAK
Takeda Pharmaceutical Co Adr
|
14.74 | 45.95B | 30.08B | 710.16M | 4.45B | 0.2182 |
|
HLN
Haleon Plc Adr
|
9.75 | 43.35B | 14.35B | 1.85B | 0 | 0.4023 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
16.58 | 18.68B | 16.54B | -1.64B | 749.00M | -1.45 |
|
UTHR
United Therapeutics Corp
|
305.61 | 13.44B | 2.99B | 1.21B | 1.13B | 25.06 |
Aytu Biopharma Inc Stock (AYTU) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-07-01 | Iniziato | Lake Street | Buy |
| 2025-06-30 | Iniziato | Ascendiant Capital Markets | Buy |
| 2021-03-30 | Iniziato | Cantor Fitzgerald | Overweight |
| 2020-05-29 | Iniziato | H.C. Wainwright | Buy |
Aytu Biopharma Inc Borsa (AYTU) Ultime notizie
What drives Aytu BioPharma Inc. stock priceFree Real-Time Stock Data - Autocar Professional
Lake Street Sees Big Upside for Aytu Biosciences (AYTU) After EXXUA Acquisition - MSN
What analysts say about Aytu BioPharma Inc. stockUnstoppable trading performance - jammulinksnews.com
Aytu BioPharma Inc. Stock Analysis and ForecastAccelerated wealth expansion - jammulinksnews.com
11 Best High Return Penny Stocks to Buy Now - Insider Monkey
Is Aytu BioPharma Inc. a good long term investmentOver 200% growth - Jammu Links News
What makes Aytu BioPharma Inc. stock price move sharplyWeekly Big Movers - beatles.ru
Why Aytu BioPharma Inc. stock attracts strong analyst attentionDouble Profit With Half Risk - beatles.ru
How Aytu BioPharma Inc. stock performs during market volatilityTrending Stock Alert - Newser
Aytu BioPharma Completes $15 Million Debt Refinancing - ACCESS Newswire
Aytu BioPharma (NASDAQ:AYTU) Downgraded by Wall Street Zen to Buy - Defense World
Aytu Boosts Liquidity with Eclipse Loan Extension - MSN
Aytu BioPharma (NASDAQ:AYTU) Now Covered by Lake Street Capital - Defense World
Aytu BioPharma (AYTU): Lake Street Initiates Coverage with Buy Rating | AYTU Stock News - GuruFocus
Lake Street Initiates Aytu BioPharma at Buy With $8 Price Target - MarketScreener
Aytu BioPharma (NASDAQ:AYTU) Coverage Initiated by Analysts at Ascendiant Capital Markets - Defense World
AYTU: Ascendiant Capital Initiates Coverage with 'Buy' Rating | AYTU Stock News - GuruFocus
This Starbucks Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday - Benzinga
Aytu BioPharma Receives Orphan Drug Designation from FDA for AR101 for Treatment of Vascular Ehlers-Danlos Syndrome - ACCESS Newswire
AYTU SEC FilingsAytu Biopharma Inc 10-K, 10-Q, 8-K Forms - Stock Titan
Aytu BioPharma (NASDAQ:AYTU) Upgraded by Wall Street Zen to Strong-Buy Rating - Defense World
15 Best Growth Stocks to Invest in for the Next 5 Years - Insider Monkey
Nobel Prize Contributor Joins Aytu to Lead $22B EXXUA Depression Drug Launch | AYTU Stock News - Stock Titan
Aytu BioPharma Expands and Extends Lending Agreement with Eclipse Following Agreement to Commercialize First-in-Class Antidepressant EXXUA(TM) - ACCESS Newswire
Aytu BioScience Expands Lending Agreement for EXXUA Launch - TipRanks
Aytu BioPharma, Inc. (NASDAQ:AYTU) Sees Significant Decline in Short Interest - Defense World
Insider Spends US$100k Buying More Shares In Aytu BioPharma - simplywall.st
CEO & Director of Aytu BioPharma Joshua Disbrow Buys 77% More Shares - Yahoo Finance
Transcript : Aytu BioPharma, Inc.Special Call - MarketScreener
Aytu Biopharma CEO Joshua Disbrow acquires $99,999 in stock By Investing.com - Investing.com India
Insider Buying: Jarrett Disbrow Acquires Shares of Aytu BioPharm - GuruFocus
Insider Buying: Jarrett Disbrow Acquires Shares of Aytu BioPharma Inc (AYTU) - GuruFocus
Aytu Biopharma chief business officer buys $24,999 in stock By Investing.com - Investing.com South Africa
Aytu Biopharma chief business officer buys $24,999 in stock - Investing.com Australia
Aytu Biopharma CEO Joshua Disbrow acquires $99,999 in stock - Investing.com Australia
Aytu Biopharma Inc Azioni (AYTU) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.34%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):